Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg downgrades Tate & Lyle to 'hold', slashes price target

(Sharecast News) - Berenberg downgraded Tate & Lyle on Wednesday to 'hold' from 'buy' and slashed the price target to 600p from 900p as it said the shares were lacking a catalyst. Tate said in a trading statement on 13 February that revenue for the year to the end of March was set to be mid-single digit percent lower and EBITDA growth was set to be towards the lower end of its guidance range of 4% to 7%. It pointed to continued geopolitical uncertainties and some pricing pressure.

"With no signs of a near-term improvement in pricing conditions or volume outlook for Tate & Lyle, we reduce our price target to GBp600 and downgrade our rating to hold," Berenberg said in a research note.

It said that following the trading statement, it now forecasts 3% price/mix declines for the Food & Beverage Solutions (FBS) division and the CP Kelco acquisition, with 5% volume growth in both businesses leading to 2% organic growth.

"We do not expect Tate to benefit from meaningful raw material deflation, which combined with negative pricing, points to margin contraction in FY 2026," it said.

"However, we believe this will be more than offset by the contribution from cost savings associated with CP Kelco; we forecast an FY 2026 EBITDA margin of 21.4% (+70bp yoy)."

Berenberg said the new price target price implies a FY 2026 price-to-earnings multiple of 12.2x, "reflecting the limited near-term growth opportunities".

At 1230 GMT, the shares were down 2.4% at 540.30p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.